LUGPA 2022: Dr. Shore on the significance of genetic testing in prostate cancer

"We want to make sure that independent urology continues to thrive by recruiting new people to independent urology. That's what we're going to try and do," said Evan R. Goldfischer, MD.

"Specifically for our transgender and gender-diverse patients, there are still insurance issues and access issues in general," said Diana K. Bowen, MD.

For patients with mCRPC who experience disease progression on novel hormonal agents (NHAs) and androgen deprivation therapy, it is important to consider when the NHA was received and whether docetaxel has been administered, explains Evan Y. Yu, MD.

ADT intensification through doublet and triplet regimens has become standard for most patients with metastatic castration-sensitive prostate cancer, Alicia Morgans, MD, MPH, explained in a presentation at the 2022 LUGPA Annual Meeting.

In an interview during the 2022 LUGPA Annual Meeting, Jason M. Hafron, MD, shared advice on optimizing advanced prostate cancer clinics, recapped the biggest advances in urologic cancer treatment in 2022, and discussed how Jelmyto treatment for UTUC has evolved over time.

"It really is a fun time to be doing urothelial cancer research, as we see patients living longer, with more durable responses, impacting their overall survival and long-term outcomes," says Arlene Siefker-Radtke, MD.